Post
Yuvi.
$LLY，昨日retatrutide头对头数据是否足以改变竞争格局？公司称试验中其减重效果超过Ozempic最高获批剂量两倍，且今天有Q3业绩电话会。临床结果可增强管线预期，但安全性、完整终点和产能仍决定商业转化。若详细数据稳健、供给扩张兑现，判断更积极；若耐受性或生产限制显现，我会下调峰值预期。
Disclaimer: OKX Orbit content is provided for informational purposes only. Learn more
Replies
No comments yet. Be the first to reply!
Trending crypto
BTC/USDTBitcoin
$65,608.4+0.00%
ETH/USDTEthereum
$1,830.49-0.01%
SOL/USDTSolana
$72.08-0.02%
Today’s market buzz
1#NVIDIA contacts Arm CEO Haas, internally predicting new CEO candidate
2#US October PPI year-on-year 6.5% below expectations
3#Anthropic launches IPO roadshow, valuation rebounds to $1.8 trillion
